Anti-HIF1A Antibodies

HIF-1-alpha Rabbit Monoclonal Antibody

The GeneBio Anti-HIF1A Antibody (Rabbit Monoclonal) is a high-affinity recombinant antibody developed to detect hypoxia-inducible factor 1 alpha (HIF-1α), a key transcription factor regulating cellular adaptation to low oxygen conditions. HIF-1α plays a central role in angiogenesis, tumor progression, energy metabolism, and hypoxia response pathways, making it an essential biomarker for cancer research, ischemic diseases, and hypoxia-related studies. This antibody provides exceptional sensitivity and specificity for HIF-1α, with strong reactivity across human samples and validated performance in multiple applications including immunohistochemistry (IHC), immunocytochemistry (ICC), Western blotting (WB), ELISA, and flow cytometry (FCM). In IHC, it enables precise detection of nuclear and cytoplasmic HIF-1α in hypoxic tissues, while in WB it identifies the expected HIF-1α band at ~120 kDa with minimal background. The antibody is equally effective in ELISA and cell-based assays, supporting both qualitative and quantitative studies of hypoxia-regulated pathways. Produced using advanced rabbit monoclonal technology, this antibody ensures reproducible results and consistent performance across batches, overcoming limitations of traditional polyclonal reagents. It is protein A affinity-purified from a recombinant expression system and formulated in a stabilizing buffer containing PBS, 1% BSA, 50% glycerol, and 0.09% sodium azide to maximize stability and shelf-life. Supplied at ~1 mg/mL concentration, it is shipped on ice and recommended for long-term storage at –20 °C, with avoidance of repeated freeze–thaw cycles. With its proven specificity, high sensitivity, and broad application utility, the GeneBio Anti-HIF1A Antibody is an essential tool for researchers investigating tumor hypoxia, angiogenic signaling, metabolic reprogramming, and cellular stress responses. It offers robust and reliable detection of HIF-1α, empowering both basic research and translational studies in oncology and hypoxia biology.